Pemigatinib

Pemigatinib is used in adults who have already received a previous treatment to treat a certain type of cholangiocarcinoma (bile duct cancer) that has spread to nearby tissues or other parts of the body and cannot be removed by surgery. Pemigatinib is also used in adults to treat a certain type of myeloid/lymphoid neoplasms (MLN; a type of blood cancer) that has not improved or has come back after other treatment. Pemigatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.

🔔 How should this medicine be used?

Pemigatinib comes as a tablet to take by mouth. For the treatment of cholangiocarcinoma, it is usually taken with or without food once daily for the first 14 days of a 21-day cycle. The cycle may be repeated as recommended by your doctor. For the treatment of myeloid/lymphoid neoplasms, it is usually taken with or without food once daily for as long as your doctor recommends that you receive treatment. Take pemigatinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take pemigatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not split, chew, or crush them.

If you vomit after taking pemigatinib, do not take another dose. Continue your regular dosing schedule.

Your doctor may decrease your dose or temporarily or permanently stop your treatment if you experience certain side effects. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with pemigatinib.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

Americans see their primary care doctors less often than they did a decade ago. Adults under 65 made nearly 25% fewer visits to primary care providers in 2016 than they did in 2018, according to National Public Radio. In the same time period, the number of adults who went at least a year without visiting a primary care provider increased from 38% to 46%.

🔔 Other uses for this medicine

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

See also  Erdafitinib